Similar results were noted for all patients with adenocarcinoma histology ( 322 patients in the docetaxel plus nintedanib group and 336 in the docetaxel plus placebo group ; median overall survival 126 months [ 95 % CI 106-151 ] vs 103 months [ 95 % CI 86-122 ] ; HR 083 [ 95 % CI 070-099 ] , p = 00359 ) , but not in the total study population ( median 101 months [ 95 % CI 88-112 ] vs 91 months [ 84-104 ] ; HR 094 , 95 % CI 083-105 , p = 02720 ) .